If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
View: This quarter has seen a focus on development and opening of government-funded and privatehealthcare infrastructure projects aimed at meeting growing domestic demand for healthcare services andpositioning the country as a regional medical tourism hub. While the country boasts a number of attractionsto gauge foreign drugmakers' interest, we continue to highlight that Oman's small population and limitedper capita spending limits pharmaceutical market growth.Headline Expenditure Projections - Pharmaceuticals: OMR175mn (US$455mn) in 2013 to OMR191mn (US$503mn) in 2014; 9.3% in localcurrency terms and 10.7% in US dollar terms. Forecast broadly in line with Q114. - Healthcare: OMR785mn (US$2.04bn) in 2013 to OMR852mn (US$2.24bn) in 2014; +8.6% in localcurrency terms and +10.0 in US dollar terms. Forecast broadly in line with Q114.
Industry View 7SWOT 10Political 12Economic 13Business Environment 14Industry Forecast 15Pharmaceutical Market Forecast 15Table: Oman Pharmaceutical Sales, Historical Data And Forecasts, 2010-2018 16Healthcare Market Forecast 17Table: Oman Healthcare Expenditure Trends, Historical Data and Forecasts, 2010-2018 18Table: Oman Government Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 18Table: Oman Private Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 19Prescription Drug Market Forecast 20Table: Oman Prescription Drug Market Indicators, Historical Data And Forecasts, 2010-2018 21Patented Drug Market Forecast 22Table: Oman Patented Drug Market Indicators, Historical Data And Forecasts 2010 - 2018 23Generic Drug Market Forecast 24Table: Oman Generic Drug Market Indicators, Historical Data And Forecasts, 2010-2018 25OTC Medicine Market Forecast 25Table: Oman Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts, 2010-2018 26Pharmaceutical Trade Forecast 27Table: Oman Pharmaceutical Trade Data And Forecasts (US$mn), 2010-2018 28Table: Oman Pharmaceutical Trade Data And Forecasts (OMRmn), 2010-2018 28Other Healthcare Data 29Key Risks To BMI's Forecast Scenario 30Macroeconomic Forecasts 31Economic Analysis 31Table: Oman - Sectors' Contribution To Overall Gdp, Current Prices 32Table: Oman - Gas Prices For Industrial Consumers 36Table: Oman - Economic Activity 40Industry Risk Reward Ratings 41Middle East And Africa Risk/Reward Ratings 41Oman Risk/Reward Ratings 49Rewards 49Risks 50Market Overview 51Industry Trends And Developments 52Industry Trends And Developments 52Epidemiology 52Communicable Diseases 52Non-Communicable Diseases 53Healthcare Sector 54Public Healthcare Sector Developments 56Private Healthcare Sector Developments 57Table: Number Of Health Centres In Oman By Region 59Table: Number And Type Of Health Institutions In Oman In 2011 60Healthcare Insurance 60Telemedicine 61Medical Tourism 62Research And Development 63Clinical Trials 65Regulatory Development 66Regulatory Developments 67Intellectual Property Regime 67Regional Harmonisation 68Pricing And Reimbursement Regime 69Competitive Landscape 73Domestic Pharmaceutical Industry 73Foreign Pharmaceutical Industry 74Pharmaceutical Distribution 75Company Profile 76Zynova/Oman Pharmaceutical Products Company 76National Pharmaceutical Industries (NPI) 79Novartis 82GlaxoSmithKline 85Sanofi 87Johnson & Johnson 89Demographic Forecast 91Demographic Outlook 91Table: Oman's Population By Age Group, 1990-2020 ('000) 92Table: Oman's Population By Age Group, 1990-2020 (% of total) 93Table: Oman's Key Population Ratios, 1990-2020 94Table: Oman's Rural And Urban Population, 1990-2020 94Glossary 95Methodology 97Pharmaceutical Expenditure Forecast Model 97Healthcare Expenditure Forecast Model 97Notes On Methodology 98Risk/Reward Ratings Methodology 99Ratings Overview 100Table: Pharmaceutical Risk/Reward Ratings Indicators 100Indicator Weightings 101